Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ENANTA PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for ENANTA PHARMACEUTICALS INC

ENTA

ENANTA PHARMACEUTICALS INC

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals is a biotechnology company specializing in the discovery and development of small molecule drugs targeting virology and immunology. Its core focus includes antiviral agents for hepatitis C, RSV, SARS-CoV-2, and hepatitis B, as well as immunology treatments for inflammatory diseases like chronic urticaria and atopic dermatitis. The company leverages chemistry-driven research, collaborates with partners like AbbVie, and aims to address significant unmet medical needs through innovative therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ENANTA PHARMACEUTICALS INC

1
1
ENANTA PHARMACEUTICALS INC Enanta Pharmaceuticals Reports 15.4% Revenue Growth in Q2 Fiscal 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
ENANTA PHARMACEUTICALS INC Enanta Pharmaceuticals Reports $18.6M Revenue and $11.9M Net Loss for December Quarter

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ENANTA PHARMACEUTICALS INC Enanta Pharmaceuticals Reports $65.3 Million Revenue for Fiscal Year Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ENANTA PHARMACEUTICALS INC Enanta Pharmaceuticals Reports Q3 Fiscal 2025 Results with $18.3M Revenue

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ENANTA PHARMACEUTICALS INC Enanta Pharmaceuticals Reports Q2 Fiscal 2025 Revenue Decline to $14.9 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ENANTA PHARMACEUTICALS INC Enanta Pharmaceuticals Reports $22.3 Million Net Loss, Revenue Declines to $17 Million

Via official filing (AI summary) | over 1 year ago | 0 comments